The n-Lorem Foundation and the EspeRare Foundation announced today a strategic collaboration to expand access in Europe to ...

SAN DIEGO--(BUSINESS WIRE)--n-Lorem, a nonprofit foundation, announced today that it will hold its third annual Nano-rare Patient Colloquium in Cambridge, Mass., where n-Lorem leaders and experts in ...

n-Lorem has received more than 330 applications and accepted more than 160 patients for potential treatment with personalized experimental ASOs discovered and developed completely in-house. n-Lorem ...

PALO ALTO, Calif. & SAN DIEGO--(BUSINESS WIRE)--n-Lorem, a nonprofit foundation, and GondolaBio, a clinical-stage biotechnology company founded in 2024 and dedicated to developing novel medicines for ...

-- Research, supported by the Wolverine Foundation and published in JCI Insights, characterizes a mutation in MAPK8IP3 that disrupts dopamine signaling SAN DIEGO--(BUSINESS WIRE)--May 08, 2025-- ...

The partners will focus on treating Swiss patients with very rare diseases and then use the framework developed to establish similar pathways throughout Europe.

PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced plans to pursue a strategic collaboration with the n-Lorem Foundation and EspeRare that we ...

n-Lorem, a nonprofit foundation, announced today that it will hold its third annual Nano-rare Patient Colloquium in Cambridge, Mass., where n-Lorem leaders and experts in the field will share updates ...